A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 735
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PA
Long Form : Pseudomonas aeruginosa
No. Year Title Co-occurring Abbreviation
2020 A clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa (IRONIC study). BSI, CI, MDR, OR
2020 A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials. ---
2020 Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. C/T, cIAIs, cUTIs, MDR, XDR
2020 Design, synthesis, and evaluation of compounds capable of reducing Pseudomonas aeruginosa virulence. QED
2020 Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. C/T, MDR, SSTIs, XDR
2020 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin. CF, DPI, UMCG
2020 Evaluation of the Revogene Carba C Assay for detection and differentiation of carbapenemase-producing Gram negative bacteria. AB, CPE, MDR
2020 Evaluation of the Saliva of Burn ICU Patients for Resistant Bacteria Harbor Metallo-beta-Lactamase Genes. AB, BICU, MBLs, MDR
2020 Ex vivo anti-microbial efficacy of various formaldehyde releasers against antibiotic resistant and antibiotic sensitive microorganisms involved in infectious keratitis. CA, DAU, DMDM, MRSA, MSSA, NP, SMG, VRE
10  2020 Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort. COPD
11  2020 In vitro and in vivo evaluation of gentamicin sulphate-loaded PLGA nanoparticle-based film for the treatment of surgical site infection. GS, PLGA, SA
12  2020 Model-informed drug development in pulmonary delivery: Preclinical pharmacokinetic-pharmacodynamic modelling for evaluation of treatments against chronic Pseudomonas aeruginosa lung infections. PK-PD
13  2020 Novel intermicrobial molecular interaction: Pseudomonas aeruginosa Quinolone Signal (PQS) modulates Aspergillus fumigatus response to iron. Af, FC, PQS, PQS, WT
14  2020 Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation. CF, CIE
15  2020 Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. CI
16  2020 Structure and redox properties of the diheme electron carrier cytochrome c4 from Pseudomonas aeruginosa. cyt c4, Ps
17  2020 The nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate/D-NO), increases survival by attenuating hyperoxia-compromised innate immunity in bacterial clearance in a mouse model of ventilator-associated pneumonia. LPS, MV, NO, VAP
18  2019 A pilot study of the in vitro antimicrobial activity and in vivo residual activity of chlorhexidine and acetic acid/boric acid impregnated cleansing wipes. AABA, CHX, EC, ESBL, MP, MRSP, MSSP, ZI
19  2019 A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas aeruginosa pulmonary infection in children with cystic fibrosis. CF, NBS
20  2019 A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections. BSIs, CnSPA, CSPA
21  2019 A systematic review and meta-analysis on Exo-toxins prevalence in hospital acquired Pseudomonas aeruginosa isolates. ---
22  2019 Anti-bacterial activity of mutant chensinin-1 peptide against multidrug-resistant Pseudomonas aeruginosa and its effects on biofilm-associated gene expression. AMP, MC1, MRPA
23  2019 Aspiration Pneumonia in Older Adults. CAAP, HCAAP, ICU, MDR, MRSA
24  2019 Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. AZLI, CF
25  2019 Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. TLR3, TNF, TRIF
26  2019 Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa. ---
27  2019 Challenges and strategies in drug delivery systems for treatment of pulmonary infections. DDS
28  2019 Community-onset Pseudomonas aeruginosa urinary sepsis in elderly people: Predictive factors, adequacy of empirical therapy and outcomes. IEAT
29  2019 Complete Killing of Agar Lawn Biofilms by Systematic Spacing of Antibiotic-Loaded Calcium Sulfate Beads. ALCSB, PJI, SA
30  2019 Contamination of a hospital plumbing system by persister cells of a copper-tolerant high-risk clone of Pseudomonas aeruginosa. DDTC
31  2019 Crystal Structure of the Type VI Secretion System Accessory Protein TagF from Pseudomonas Aeruginosa. DENN, PAL, PCR, tagA-P, tssA-M
32  2019 Development of Chronic Pseudomonas aeruginosa-Positive Respiratory Cultures in Children with Tracheostomy. ---
33  2019 Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa. EP, MDR, MIC, PDR
34  2019 Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). BE, TIP
35  2019 Electrical stimulation disrupts biofilms in a human wound model and reveals the potential for monitoring treatment response with volatile biomarkers. ES, VOC
36  2019 Electrochemical monitoring of the impact of polymicrobial infections on Pseudomonas aeruginosa and growth dependent medium. 5-MCA, EC, LB, PYO, SA, T-CUAs, TSB
37  2019 Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study. CF
38  2019 Exhaled breath metabolomics reveals a pathogen-specific response in a rat pneumonia model for two human pathogenic bacteria: a proof-of-concept study. AUROCCs, CCRs, SIFT-MS, SP, TD-GC-MS
39  2019 Formulation development and in vitro evaluation of gentamicin sulfate-loaded PLGA nanoparticles based film for the treatment of surgical site infection by Box-Behnken design. DoE, GS, PBS, PDI, PLGA, PNPs, PVA, SA, SEM, SSI, SWF, TEM, TS, XRD
40  2019 Genetic deletion of Sphk2 confers protection against Pseudomonas aeruginosa mediated differential expression of genes related to virulent infection and inflammation in mouse lung. ANOVA, PW, S1P, SphK, WT
41  2019 Hot topics and current controversies in non-cystic fibrosis bronchiectasis. NCFB
42  2019 Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. MDR-PA
43  2019 In vitro evaluation of the effectiveness of alkaline peroxide solutions in reducing the viability of specific biofilms. Bs, CA, Cg, CT, EC, Ef, EF, EM, EQ, FI, KI, KR, KU, MI, SA, SM
44  2019 Involvement of TLR4 and PPAR-alpha Receptors in Host Response and NLRP3 Inflammasome Activation, Against Pulmonary Infection With Pseudomonas Aeruginosa. IT, PPARs, TLR4
45  2019 Isolation of Enterobacteriaceae in airway samples is associated with worse outcome in preschool children with cystic fibrosis. EB
46  2019 Lactobacilli intra-tracheal administration protects from Pseudomonas aeruginosa pulmonary infection in mice - a proof of concept. IL
47  2019 Lung infection caused by Pseudomonas aeruginosa in a CD26/DPP4 deficient F344 rat model. DPP4
48  2019 Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection. QSIs
49  2019 Multidrug-resistant Pseudomonas aeruginosa and mortality in mechanically ventilated ICU patients. CI, HR, MDR, VAP
50  2019 Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. CF
51  2019 Necrotizing Otitis Externa-Analysis of 83 Cases: Clinical Findings and Course of Disease. NOE
52  2019 Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against Pseudomonas aeruginosa lung infection. BALF, ED, MUC1, NEU1, PAK
53  2019 Novel cystamine-core dendrimer-formulation rescues DeltaF508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy. CF
54  2019 Pilot Ex Vivo and In Vitro Evaluation of a Novel Foley Catheter with Antimicrobial Periurethral Irrigation for Prevention of Extraluminal Biofilm Colonization Leading to Catheter-Associated Urinary Tract Infections (CAUTIs). CA, CAUTIs, EC, Ef, KB, PR
55  2019 Platelets inhibit apoptotic lung epithelial cell death and protect mice against infection-induced lung injury. ---
56  2019 Prophylactic and therapeutic protection of human IgG purified from sera containing anti-exotoxin A titers against pneumonia caused by Pseudomonas aeruginosa. ETA
57  2019 Protein surface charge effect on 3D domain swapping in cells for c-type cytochromes. cyt, Cyts, HT, SV
58  2019 Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. CF, PKC, S1P, SphK
59  2019 Radiolabeled Cationic Peptides for Targeted Imaging of Infection. i.m, PET, SA, SUV
60  2019 Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa. T3SS
61  2019 Relationship among clinical periodontal, microbiologic parameters and lung function in participants with chronic obstructive pulmonary disease. CAL, COPD, COPD, Kp, OHI-S, Pg, S. p
62  2019 Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis. SEM
63  2019 Secretory IgA-mediated immune response in saliva and early detection of Pseudomonas aeruginosa in the lower airways of pediatric cystic fibrosis patients. CF, LAW, sIgA
64  2019 Sputum Exosomal microRNAs Profiling Reveals Critical Pathways Modulated By Pseudomonas aeruginosa Colonization In Bronchiectasis. DEMs
65  2019 The anti-sigma factor MucA of Pseudomonas aeruginosa: Dramatic differences of a mucA22 vs. a DeltamucA mutant in anaerobic acidified nitrite sensitivity of planktonic and biofilm bacteria in vitro and during chronic murine lung infection. CF, COPD, NO
66  2019 The miR-183/96/182 Cluster Regulates Macrophage Functions in Response to Pseudomonas aeruginosa. LPS, miRNAs
67  2019 The Prevalence of Pseudomonas Aeruginosa Infection Over a Ten-Year Period in Children with Cystic Fibrosis CF, CFRI
68  2019 The role of geographical location and climate on recurrent Pseudomonas infection in young children with Cystic Fibrosis. ---
69  2019 The toxin from a ParDE toxin-antitoxin system found in Pseudomonas aeruginosa offers protection to cells challenged with anti-gyrase antibiotics. ---
70  2019 TIPE2 Suppresses Pseudomonas aeruginosa Keratitis by Inhibiting NF-kappaB Signaling and the Infiltration of Inflammatory Cells. ELISA, HCECs, IL-1beta, IL-6, LPS, mRNA, NF-kappaB, shRNA, TNF-alpha, WT
71  2019 Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis. CF, CI, HR, MD, SD, TIS
72  2019 Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers. PCD
73  2019 Ventilator associated pneumonia due to carbapenem resistant microorganisms in children. AB, CRAB, PICU, VAP
74  2019 Vertebrate odorant binding proteins as antimicrobial humoral components of innate immunity for pathogenic microorganisms. CA, OBP, QS, QSM, TKA
75  2018 A Unique Pattern of Staphylococcal Scalded Skin Syndrome-Like Erosions in Patients with Atopic Dermatitis: Dermatitis flammeus. AD
76  2018 Altered community compositions of Proteobacteria in adults with bronchiectasis. ---
77  2018 Antibacterial and Biofilm Modulating Potential of Ferulic Acid-Grafted Chitosan against Human Pathogenic Bacteria. LM, MIC, SA
78  2018 Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. OR, PA-R
79  2018 Antimicrobial Studies Using the Therapeutic Tissue Cross-Linking Agent, Sodium Hydroxymethylglycinate: Implication for Treating Infectious Keratitis. CA, MRSA, MSSA, SMG, VRE
80  2018 Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. TIS
81  2018 Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm. XDR-PA
82  2018 Beta-Defensin 2 and 3 Promote Bacterial Clearance of Pseudomonas aeruginosa by Inhibiting Macrophage Autophagy through Downregulation of Early Growth Response Gene-1 and c-FOS. Egr-1
83  2018 Bio-active nanocomposite films based on nanocrystalline cellulose reinforced styrylquinoxalin-grafted-chitosan: Antibacterial and mechanical properties. Bs, EC, SA
84  2018 Caregiver burden of parents of young children with cystic fibrosis. CF, US, VAS
85  2018 CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced by Pseudomonas aeruginosa. CF, CHAC1, hAECBs
86  2018 Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review. CF, MDR
87  2018 Characteristics of a Pseudomonas aeruginosa induced porcine sepsis model for multi-organ metabolic flux measurements. BW, CRP, IL-6, SIRS
88  2018 Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis. COPD, CS, CSE
89  2018 Comparison between corneal cross-linking, topical antibiotic and combined therapy in experimental bacterial keratitis model. CXL, MRSA
90  2018 Comparison of clinical characteristics and antibiotic susceptibility between Pseudomonas aeruginosa and P. putida keratitis at a tertiary referral center: a retrospective study. PP
91  2018 Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. fla, KP, O-PS
92  2018 Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. CFTR
93  2018 Does screening neonates in the neonatal intensive care unit for Pseudomonas aeruginosa colonization help prevent infection? NICU, VNTR
94  2018 Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. AET, TIS
95  2018 Effects of a small, volatile bacterial molecule on Pseudomonas aeruginosa bacteria using whole cell high-resolution magic angle spinning nuclear magnetic resonance spectroscopy and genomics. 2-AA, HR-MAS, NMR
96  2018 Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. CAP, ICU
97  2018 Enhanced sterilization and healing of cutaneous pseudomonas infection using 5-aminolevulinic acid as a photosensitizer with 410-nm LED light. ALA, PDT, PpIX
98  2018 Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. CAZ/AVI, MDR, XDR
99  2018 Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study. ESBL, MDRO
100  2018 In vitro antibacterial and early stage biofilm inhibitory potential of an edible chitosan and its phenolic conjugates against Pseudomonas aeruginosa and Listeria monocytogenes. CCA, CPCs, LM